Skip to main content
Midas Edge

SNDL Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

View on SEC.gov

About this filing

The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.

FY2023 · Filed Mar 21, 2024

Use the contents to explore the available documents and sections.

SNDL$1.42+2.5%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.2 · Interest in associate

Interest in associate

The Company holds a 25% equity interest in its associate Pathway RX Inc. (“Pathway”). Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a range of medical cannabis. The carrying amount of the Company’s interest in Pathway is nil.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.